Welcome to the AD/PD™ 2021 Interactive Program
The congress will officially run on Central European Time (CET) - Barcelona Time
To convert the congress times to your local time Click Here
Icons Legend: ![]()
- Live Session | 
- On Demand Session | 
- On Demand with Live Q&A
The viewing of sessions, cannot be accessed from this conference calendar. All sessions are accessible via the Main Lobby.
Session Description
Join Eisai for a virtual symposium focusing on the central role of amyloid beta (Aβ) in the pathophysiology of Alzheimer’s disease (AD). Our expert faculty will provide a comprehensive overview of the evidence supporting Aβ alteration as an early event within the AD continuum, as well as a presentation of the latest developments regarding in vivo biomarkers of Aβ. The program will begin by reviewing the genetic evidence supporting a role for Aβ in AD, and cover the different Aβ species and their roles in brain toxicity. Finally, we will discuss the latest developments concerning in vivo biomarkers of Aβ, as well as amyloid positron emission tomography imaging and cerebrospinal fluid measures of Aβ dyshomeostasis.
THE SCIENCE BEHIND THE Aβ PATHWAY IN ALZHEIMER’S DISEASE
SUPPORTED BY EISAI
WELCOME AND INTRODUCTIONS
THE BIOLOGICAL AND GENETIC EVIDENCE OF THE Aβ PATHWAY
LATE ONSET (SPORADIC) ALZHEIMER’S DISEASE: TOPOGRAPHIC AGGREGATION OF Aβ AMYLOID IS RELATED TO THE NORMAL FUNCTION OF AMYLOID PRECURSOR PROTEIN (APP) AND THE FAILURE OF CLEARANCE OF Aβ AMYLOID
BIOMARKERS TO IDENTIFY Aβ IN VIVO
Q&A SESSION